In 2021, McGuire, D.K. et al. [43] conducted a meta-analysis using the PubMed database to assess the cardiovascular and renal effects of SGLT2 inhibitors in patients with T2DM. Here, SLC5A2 is linked to type 2 diabetes mellitus.